Stay informed about EMBL news by subscribing to press releases.
For more information please contact the Press Officer:
Meyerhofstraße 1, Heidelberg, 69117, Germany
Hinxton, 27 March 2014 Where do you start when developing a new medicine? A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of ‘big data’ and genome sequencing to improve the success rate for discovering new medicines. The new Centre for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.
Heidelberg, 7 March 2014 Slovak Republic becomes EMBL Prospect Member State EMBL welcomes the Slovak Republic as the first country to join its new Prospect Member scheme. In a Statement of Intent signed last month, the Slovak Republic and EMBL agree to explore the possibilities for long-term cooperation, with a view to the country becoming a full Member State within three years.
Heidelberg, 24 February 2014 Pan-European imaging infrastructure gains momentum Europe is uniting to make state-of-the-art imaging technologies accessible to biomedical researchers throughout the continent in a concerted manner. EMBL and seven countries have signed the Euro- BioImaging Memorandum of Understanding. In the coming months, the signatories will work together towards the implementation and construction of this new pan-European infrastructure for imaging technologies. All European countries are invited to participate and several European nations are already set to follow suit.
Monterotondo, 2 February 2014 Making your brain social Scientists have identified, for the first time, a way in which the decreased functional connectivity seen in the brain of many people with autism can come about: it can be caused by cells called microglia failing to trim connections between neurons, researchers from EMBL Monterotondo, the Istituto Italiano di Tecnologia and La Sapienza University demonstrate in a study published today in Nature Neuroscience.
Heidelberg, 5 December 2013 Light at the ends of the tunnel When scientists in the Beck group at EMBL Heidelberg determined what one of the nuclear pore’s main building blocks – Nup107 – looks like and how it is arranged, they found clues to the flexibility of this tunnel into the nucleus. Their study was recently featured on the cover of Cell.
Monterotondo, 10 November 2013 What are you scared of? What do bullies and sex have in common? Based on work by scientists at EMBL Monterotondo, it seems that the same part of the brain reacts to both. In a study published today in Nature Neuroscience, the researchers found that – at least in mice – different types of fear are processed by different groups of neurons. The findings could have implications for addressing phobias and panic attacks in humans.
Heidelberg, 23 October 2013 Bigger, better, faster The molecular machine that makes essential components of ribosomes is like a Swiss-army knife, researchers at EMBL Heidelberg and collaborators have found. By determining the 3-dimensional structure of this machine, called RNA polymerase I, for the first time, the scientists found that it incorporates modules which prevent it from having to recruit outside help. The findings, published online today in Nature, can help explain why this protein works faster than its better-studied counterpart.
Heidelberg, 13 October 2013 Choreographed origami Like a budding origami artist pencilling in the folds, the cell uses tags called methyl groups to help mark where and how an RNA molecule should be folded. In work published online today in Nature, scientists at EMBL Heidelberg have discovered that, to build ribosomes, pairs of these tags are added in a specific order.
Heidelberg, 25 September 2013 Without a trace Cells in a zebrafish embryo determine which direction they move in by effectively erasing the path behind them, scientists at EMBL Heidelberg have discovered. The findings, published online today in Nature, could have implications not just for development but also for cancer and metastasis.
Heidelberg, 12 September 2013 Potential new drug target for cystic fibrosis Scientists at EMBL Heidelberg, Regensburg University, and the University of Lisboa have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Policy regarding use
Press and Picture Releases
EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.